Johnson & Johnson Says FDA Approves ICOTYDE, IL-23 Receptor Antagonist For Treatment Of Moderate-To-Severe Plaque Psoriasis
unknown
📅 Published: 2026-03-18 07:52
📰 Source: Benzinga
📝 Words: 32
📝 Article Content
Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pillICOTYDE offers an innovative new option for patients
📄 Summary
Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pillICOTYDE offers an innovative new option for patients
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-03-20 04:09:41
Updated At:
2026-03-20 04:09:41
Scraping Job ID:
N/A
Stock Mentions:
AMP - Ameriprise Financial Inc.
Relevance: N/A